📣 VC round data is live. Check it out!
- Public Comps
- Ginkgo Bioworks
Ginkgo Bioworks Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ginkgo Bioworks and similar public comparables like Grupa Azoty, Intrepid Potash, Gujarat State Fertilizers, Itafos and more.
Ginkgo Bioworks Overview
About Ginkgo Bioworks
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Founded
2008
HQ

Employees
834
Website
Financials (LTM)
EV
$621M
Valuation Multiples
Start free trialGinkgo Bioworks Financials
Ginkgo Bioworks reported last 12-month revenue of $161M and negative EBITDA of ($171M).
In the same LTM period, Ginkgo Bioworks generated $116M in gross profit, ($171M) in EBITDA losses, and had net loss of ($305M).
Revenue (LTM)
Ginkgo Bioworks P&L
In the most recent fiscal year, Ginkgo Bioworks reported revenue of $170M and EBITDA of ($255M).
Ginkgo Bioworks is unprofitable as of last fiscal year, with gross margin of 72%, EBITDA margin of (150%), and net margin of (184%).
Financial data powered by Morningstar, Inc.
Ginkgo Bioworks Stock Performance
Ginkgo Bioworks has current market cap of $583M, and enterprise value of $621M.
Market Cap Evolution
Ginkgo Bioworks' stock price is $8.93.
Ginkgo Bioworks share price increased by 5.6% in the last 30 days, and by 28.5% in the last year.
Ginkgo Bioworks has an EPS (earnings per share) of $-4.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $621M | $583M | -13.5% | 5.6% | 32.3% | 28.5% | $-4.79 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGinkgo Bioworks Valuation Multiples
Ginkgo Bioworks trades at 3.9x EV/Revenue multiple, and (3.6x) EV/EBITDA.
EV / Revenue (LTM)
Ginkgo Bioworks Financial Valuation Multiples
As of May 9, 2026, Ginkgo Bioworks has market cap of $583M and EV of $621M.
Ginkgo Bioworks has a P/E ratio of (1.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ginkgo Bioworks Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ginkgo Bioworks Margins & Growth Rates
In the most recent fiscal year, Ginkgo Bioworks reported gross margin of 72%, EBITDA margin of (150%), and net margin of (184%).
Ginkgo Bioworks Margins
Ginkgo Bioworks Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ginkgo Bioworks Operational KPIs
Ginkgo Bioworks' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Ginkgo Bioworks Competitors
Ginkgo Bioworks competitors include Grupa Azoty, Intrepid Potash, Gujarat State Fertilizers, Itafos, SunOpta, Takara Bio, Codexis, Biotest, Anhui Huaheng and Darwin.
Most Ginkgo Bioworks public comparables operate across Bioindustrials, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.7x | 0.7x | 45.8x | 19.1x | |||
| 1.4x | 1.5x | 7.9x | 6.9x | |||
| 0.6x | 0.5x | 5.7x | 6.9x | |||
| 0.8x | 0.8x | 2.3x | 2.7x | |||
| 1.4x | 1.4x | 14.4x | 12.0x | |||
| 2.6x | 2.6x | 17.9x | — | |||
| 3.8x | 3.7x | (9.4x) | (9.8x) | |||
| 1.8x | — | 10.7x | — | |||
This data is available for Pro users. Sign up to see all Ginkgo Bioworks competitors and their valuation data. Start Free Trial | ||||||
Ginkgo Bioworks Funding History
Before going public, Ginkgo Bioworks raised $798M in total equity funding, across 7 rounds.
Last private valuation of Ginkgo Bioworks was $4B, after raising $290M in September 2019 from Cascade Investment, General Atlantic, Meros Equity Global Management, and 2 other investors.
Ginkgo Bioworks Funding Rounds
Ginkgo Bioworks M&A Activity
Ginkgo Bioworks has acquired 15 companies to date.
Last acquisition by Ginkgo Bioworks was on April 11th 2024. Ginkgo Bioworks acquired AgBiome (The GENESIS unit) for undisclosed valuation.
Latest Acquisitions by Ginkgo Bioworks
| Description | AgBiome's GENESIS unit is a microbial discovery platform based in Research Triangle Park, North Carolina, curating one of the world's largest collections of plant-associated microbes. It screens billions of microbes annually to identify novel bioactives for crop protection, personal care, and industrial applications. The unit licenses strains to partners developing sustainable ingredients free of synthetic chemicals. | Modulus Therapeutics (cell therapy platform unit) is a Boston-based biotechnology entity developing libraries of chimeric antigen receptor designs and switch receptors for next-generation cell therapies. The platform targets solid tumors and hematologic malignancies, enabling tunable CAR-T therapies with enhanced safety profiles. Modulus Therapeutics licenses these assets to partners in the immuno-oncology space. | Reverie Labs is a San Francisco-headquartered biotech firm using machine learning for small-molecule drug discovery in oncology and neurology. As a Y Combinator Winter 2018 company, Reverie Labs applies generative models to optimize lead compounds reducing preclinical timelines. The team generates novel chemical structures screened via in silico assays against protein targets. Reverie Labs partners with CROs for synthesis and holds patents on AI-optimized inhibitors. | Patch Biosciences is a San Francisco-based biotech firm engineering gene therapies through machine learning-optimized DNA design and high-throughput synthesis. Its platform generates adeno-associated virus capsids and payloads targeting neuromuscular, ocular, and liver diseases. | |
| HQ Country | |||||
| HQ City | Raleigh, NC | Seattle, WA | — | New York City, NY | |
| Deal Date | 11 Apr 2024 | 2 Apr 2024 | 28 Feb 2024 | 28 Feb 2024 | |
| Valuation | undisclosed | undisclosed | $4M | $14M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Ginkgo Bioworks acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Ginkgo Bioworks Investment Activity
Ginkgo Bioworks has invested in 5 companies to date.
Latest investment by Ginkgo Bioworks was on July 5th 2022. Ginkgo Bioworks invested in Phytolon in their $15M Series A round (EV/Revenue multiple of ).
Latest Investments by Ginkgo Bioworks
| Description | Phytolon is a Lund-based biotechnology company that ferments yeast strains to produce natural carotenoids including astaxanthin and beta-carotene for food coloring. Its microbial production process replaces synthetic dyes and chemical extraction from plants, targeting beverages, dairy, and confectionery products. Phytolon partners with global food ingredient suppliers to scale manufacturing in Europe. The firm holds patents on genetically engineered yeasts optimized for high-yield pigment secretion in fermenters. | Cambium is a Boston-based deep tech company engineering biomaterials from fungal mycelium for defense armor, aerospace components, and renewable energy panels. Founded in 2020, it combines synthetic biology with automation to produce leather alternatives stronger than Kevlar. Cambium supplies prototypes to DARPA and NASA programs. | Allonnia is a biotechnology firm developing microbial solutions for environmental remediation, waste upcycling, and carbon capture. Based in Boston, Massachusetts, the company engineers bacteria to treat contaminated water, restore mining sites, and convert industrial waste into valuable products like biofuels. Allonnia's platform has been deployed at Superfund sites and mining operations in the United States and South America. Named a finalist in Fast Company's 2023 Next Big Things in Tech for its BioAir product, which reduces methane emissions from landfills, Allonnia raised $35 million in Series A funding in 2023. The firm partners with mining giants and wastewater utilities to lower CO2 footprints and achieve regulatory compliance. | Genomatica is a San Diego-based company engineering biobased technologies for chemical production from renewable feedstocks. It has commercialized processes for 1,4-butanediol used in biodegradable plastics and apparel, and butylene glycol for cosmetics via its Brontide product. The firm pursues bio-nylon and has received the Kirkpatrick Award and ICIS Innovation Award for its advancements. | |
| HQ Country | |||||
| HQ City | Yokneam Illit | Mojave, CA | Boston, MA | San Diego, CA | |
| Deal Date | 5 Jul 2022 | 14 Sep 2021 | 22 Oct 2020 | 3 Oct 2018 | |
| Round | Series A | Seed | Series A | Undisclosed stage | |
| Raised | $15M | $8M | $40M | $90M | |
| Investors | Agriline; Arkin Holdings; Cibus Fund; DSM Venturing; Ginkgo Bioworks; Millenium Food-Tech; OpenValley; Stern Tech; Trendlines Group; Yossi Ackerman | 8VC; Ginkgo Bioworks | Battelle; Cascade Investment; General Atlantic; Ginkgo Bioworks; Viking Global Investors | Casdin Capital; Ginkgo Bioworks; Viking Global Investors | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Ginkgo Bioworks investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ginkgo Bioworks
| When was Ginkgo Bioworks founded? | Ginkgo Bioworks was founded in 2008. |
| Where is Ginkgo Bioworks headquartered? | Ginkgo Bioworks is headquartered in United States. |
| How many employees does Ginkgo Bioworks have? | As of today, Ginkgo Bioworks has over 834 employees. |
| Who is the CEO of Ginkgo Bioworks? | Ginkgo Bioworks' CEO is Jason Kelly. |
| Is Ginkgo Bioworks publicly listed? | Yes, Ginkgo Bioworks is a public company listed on NYSE. |
| What is the stock symbol of Ginkgo Bioworks? | Ginkgo Bioworks trades under DNA ticker. |
| When did Ginkgo Bioworks go public? | Ginkgo Bioworks went public in 2021. |
| Who are competitors of Ginkgo Bioworks? | Ginkgo Bioworks main competitors include Grupa Azoty, Intrepid Potash, Gujarat State Fertilizers, Itafos, SunOpta, Takara Bio, Codexis, Biotest, Anhui Huaheng, Darwin. |
| What is the current market cap of Ginkgo Bioworks? | Ginkgo Bioworks' current market cap is $583M. |
| What is the current revenue of Ginkgo Bioworks? | Ginkgo Bioworks' last 12 months revenue is $161M. |
| What is the current revenue growth of Ginkgo Bioworks? | Ginkgo Bioworks revenue growth (NTM/LTM) is (9%). |
| What is the current EV/Revenue multiple of Ginkgo Bioworks? | Current revenue multiple of Ginkgo Bioworks is 3.9x. |
| Is Ginkgo Bioworks profitable? | No, Ginkgo Bioworks is not profitable. |
| What is the current EBITDA of Ginkgo Bioworks? | Ginkgo Bioworks has negative EBITDA and is not profitable. |
| What is Ginkgo Bioworks' EBITDA margin? | Ginkgo Bioworks' last 12 months EBITDA margin is (107%). |
| What is the current EV/EBITDA multiple of Ginkgo Bioworks? | Current EBITDA multiple of Ginkgo Bioworks is (3.6x). |
| How many companies Ginkgo Bioworks has acquired to date? | As of May 2026, Ginkgo Bioworks has acquired 15 companies. |
| What was the largest acquisition by Ginkgo Bioworks? | $300M acquisition of Zymergen on 25th July 2022 was the largest M&A Ginkgo Bioworks has done to date. |
| What companies Ginkgo Bioworks acquired? | Ginkgo Bioworks acquired Zymergen, Warp Drive Bio, FGen, Circularis Biotechnologies, Patch Biosciences, Altar, Reverie Labs, Bitome, Novogy, Project Beacon COVID-19, and 5 other companies. |
| In how many companies Ginkgo Bioworks has invested to date? | As of May 2026, Ginkgo Bioworks has invested in 5 companies. |
| What was the last Ginkgo Bioworks investment? | On 5th July 2022 Ginkgo Bioworks invested in Phytolon, participating in a $15M Series A round, alongside Agriline, Arkin Holdings, Cibus Fund, DSM Venturing, Millenium Food-Tech, OpenValley, Stern Tech, Trendlines Group, and Yossi Ackerman. |
| In what companies Ginkgo Bioworks invested in? | Ginkgo Bioworks invested in Joyn Bio, Genomatica, Allonnia, Phytolon, and Cambium. |
See public comps similar to Ginkgo Bioworks
Lists including Ginkgo Bioworks
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

